Rationale: Neuroendocrine cell hyperplasia of infancy (NEHI) typically presents in infancy with tachypnea, retractions, and hypoxemia. Some infants have failure to
| INTRODUCTION
Neuroendocrine cell hyperplasia of infancy (NEHI) is a form of childhood interstitial lung disease (ILD) that presents with insidious onset of tachypnea, retractions, and hypoxemia in infants. [1] [2] [3] [4] The chest computed tomography (CT) findings, pulmonary function test patterns, and lung biopsy diagnostic criteria for NEHI have been well defined. [4] [5] [6] [7] While genetic mechanisms play a role in at least some cases, identification of an underlying pathogenic trigger has remained elusive in most children. No specific treatments are available and disease management remains limited to supportive care such as supplemental oxygen. Children with NEHI improve over time, with no reported mortality, though the pace and clinical course are highly variable. Recent data indicate persistence of disease manifestations into later childhood and even adulthood in some cases, while others improve remarkably by preschool years. 2, [8] [9] [10] [11] [12] The factors which modify disease course and drive these variable clinical outcomes are poorly understood.
Failure to thrive is a frequent though not universal feature in children with NEHI, 4, 7, 10, 11 and our clinical experience is that nutritional supplementation is provided in many cases. Nutrition is fundamental in treatment of other lung diseases such as cystic fibrosis (CF), where achieving body mass index (BMI) goals are prioritized to maintain lung function over time, and higher BMI goals exist for individuals with CF compared to the rest of the population. 13, 14 However, in NEHI, it is unknown whether malnutrition contributes to and/or is a marker of pulmonary morbidity, and there are no established targets for nutritional status. Further, other than failure to thrive, extra-pulmonary morbidity has not been reported in children with NEHI. Our objective was to identify factors and comorbidities that may associate with and drive variability in the respiratory disease burden and clinical course of NEHI. Here we report the duration of oxygen use in NEHI and provide novel longitudinal data on failure to thrive in this population and its association with respiratory morbidity.
Some of these data have previously been presented in abstract form. were individuals 0-18 years of age with NEHI diagnosis and informed parental consent. Potential subjects were excluded if there was a lack of diagnostic confirmation or insufficient records for review.
Diagnosis was confirmed based on established clinical, radiologic, or histologic criteria. 3, 6 Parents/guardians of children with NEHI were asked to report their perspectives on the health status of their children using an exploratory electronic questionnaire to identify domains of concern.
Additional clinical data were obtained via chart review and interview of parents. Growth status measures included provider diagnosis of failure to thrive, weight-for-age percentile at time of oxygen initiation, and growth trends over the first 5 years of life at pre-specified ages based on the underwent lung biopsy, at a median age of 11 months (95%CI 6.5-15.5). Thus, collectively, these data revealed a delay in diagnosis of 5.5 months from symptom onset to NEHI diagnosis.
Because a 2010 publication prompted greater reliance on chest CT findings rather than lung biopsy for NEHI diagnosis, 5 we examined whether the delays in NEHI diagnosis have changed over time. We found that NEHI diagnosis occurred at an older age for subjects born Chart review and parent phone interviews were performed to verify data from the electronic questionnaire (Table 2 ). Developmental delays, including domains of speech and language development, fine motor skills, gross motor skills, and sensory processing, were documented in 38% of subjects. Interventions included speech feeding therapy for 37%, speech language therapy for 24%, physical therapy for 17%, and occupational therapy for 17%.
In the questionnaire, 65% of parents reported they had been concerned about their child's growth. Seventy-four percent of this cohort had a diagnosis of failure to thrive documented by a medical provider at some time during their clinical course. Thirteen (31%) subjects underwent gastrostomy tube (g-tube) placement, at a median age of 9 months (95%CI 3.6-14.4 months). We requested historical growth records from primary care and subspecialty providers to validate and further investigate these findings; acceptable longitudinal weight data were available for n = 33 (79%) of subjects and longitudinal BMI and weight-for-length data were available for n = 26 (62%).
Among subjects with available serial growth data, 77% had failure to thrive based on decline in weight-for-length/BMI over two major growth curves or falling below the 3rd percentile for age and sex. Table 2) .
To evaluate for a potential correlation between growth failure and respiratory morbidity, the duration of continuous supplemental oxygen was defined as the primary endpoint. A diagnosis of failure to thrive at any time during clinical course was associated with longer Note that median duration reflects duration at time of study performance and is ongoing in many young subjects (as displayed in Figure 3) . 
| DISCUSSION
In the largest reported cohort of children with NEHI, this study provides novel insights into natural history of this rare disease, including longitudinal growth trajectories and duration of supplemental oxygen use. Though a common question asked by parents, the duration of oxygen supplementation in NEHI has not been comprehensively evaluated. We found that 50% of subjects had discontinued Failure to thrive has been reported to be common in childhood ILD, 3, 17, 18 and the approximately 75% rate of failure to thrive diagnosis in our study is consistent with prevalence rates of failure to thrive in smaller NEHI cohorts. 2, 4, 5, 11, 18, 19 Longitudinal trajectories of weightfor-length/BMI percentile have not been previously analyzed in NEHI.
We observed that a decline in weight-for-length percentiles occurred within the first few months of life, with nadir around 4 months of age followed by relative percentile recovery. Interestingly, the improvement in growth trajectory for the cohort occurred prior to the median age for g-tube placement among the subset (31%) receiving that intervention. Further, several subjects exhibited persistently low weight-for-age percentiles and lack of catch up growth to date despite nutritional supplementation via g-tube (Supplemental Figure S2 ).
Nutrition and growth have been extensively studied in other pediatric pulmonary conditions, including CF and bronchopulmonary dysplasia. Specific to CF, it has been repeatedly demonstrated that lung function correlates with BMI percentiles, and nutritional optimization is highly emphasized in management. 20, 21 Unlike CF, children with NEHI do not have malabsorption or chronic infectious processes to account for growth failure; rather, the prominent tachypnea associated with NEHI in infants is hypothesized to increase resting energy expenditure.
We found that children with failure to thrive had a longer duration of continuous supplemental oxygen requirement. The nature of this interaction is unclear. While poor growth and nutritional status may directly affect the respiratory course, it is possible that parents/ providers may be less likely to wean oxygen if growth concerns remain.
As reliable weight and length data were not available at the time of oxygen initiation for many subjects, further studies are required to define whether failure to thrive is a prognostic biomarker, as opposed to a marker for more significant respiratory disease.
Our data indicate an overall delay of 5. A limitation of this study is the retrospective study design, including that growth data were derived from chart review of records rather than protocol driven measurements. Although detailed growth data were not available for all subjects, the prevalence of failure to thrive was similar based on medical record diagnosis within the entire cohort and the subgroup with growth curve analysis, suggesting that this was likely a representative sample of the full cohort in this study.
Duration of oxygen supplementation was selected as the primary endpoint for pulmonary morbidity in this study, as this is important to NEVEL ET AL.
| 661 families and may reflect functional limitations in these subjects. Serial objective measurements such as pulmonary function testing and overnight polysomnograms were not available for most of these young subjects and will be informative for future studies of pulmonary outcomes. Although this study represents the largest cohort to date for this rare disease, the sample size provided limited statistical strength to develop predictive tools from this data. Approximately half of subjects did not follow in our center for continuity of pulmonary care, and therefore, the diagnostic and clinical course reported here reflects more diverse clinical experiences across the NEHI population beyond practice patterns at our center.
In conclusion, this study provides new insights into disease burden, extra-pulmonary morbidity, and clinical patterns of oxygen use and growth in children with NEHI. This information regarding the clinical and diagnostic course as well as extra-pulmonary disease manifestations is useful to both providers and affected families and should inform future studies. Understanding the clinical variability in NEHI may enable the development of strategies to improve these modifiable factors and potentially improve pulmonary course in this disease.
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